The Institute for Global Health is enrolling participants, aged 18-70, who are living with HIV and on stable ART (antiretroviral treatment). The purpose of this study is to test two investigational drugs, budigalmab and ABBV-382 and learn what kinds of side effects or other safety problems might be seen when the combination is given. Also to learn if budigalimab and/or ABBV-382 can help the body control the HIV viral load after ART has been stopped. Your participation in this study may include approximately 17 study visits to the research center and 8 phone call visits. The study duration is approximately 57 weeks.